Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Sarcoma 2Gynecologic 2Gastrointestinal 2Other solid neoplasm 1Head & Neck 1Genitourinary 1

Conditions

Uterine Neoplasms 1Uterine Cervical Neoplasms 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Kidney Neoplasms 1Head and Neck Neoplasms 1Gastrointestinal Stromal Tumors 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 166Cisplatin 112Cetuximab 76Nivolumab 52Carboplatin 51Fluorouracil 48Paclitaxel 42Docetaxel 37Gemcitabine 30Radiotherapy 28Capecitabine 19Cyclophosphamide 18durvalumab 17Injections 17lenvatinib 16atezolizumab 16cemiplimab 15spartalizumab 13fludarabine 13avelumab 12Ipilimumab 12Pemetrexed 11130-nm albumin-bound paclitaxel 11Oxaliplatin 10Gefitinib 10tremelimumab 9Drug Therapy 9tislelizumab 8epacadostat 8budigalimab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × OSI 930 × Head & Neck × Clear all
NCT00513851 2011-09-27

Phase 1 Study of OSI-930 in Cancer Patients

Astellas Pharma Inc

Phase 1 Completed
60 enrolled
GastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡